보령

003850KOSPI의약품 제조업

54.6 / 100

Reference Date: 2026-06-10

Financial Score20.0 / 40

News Sentiment19.6 / 25

Momentum5.0 / 20

Disclosure10.0 / 15

AI Analysis: ROE significantly exceeds the industry average but the high debt ratio poses financial risk. Declined 13.7% over the past month, and news sentiment is positive.

Company InformationBased on 2025 Annual Report

Business Overview

Boehringer focuses on strengthening its own product portfolio and building a stable portfolio centered on chronic diseases to enhance profitability. In 2024, the company achieved sales of 1.171 trillion KRW and operating profit of 70.5 billion KRW. It leverages manufacturing competitiveness, R&D capabilities, sales and marketing strength, and the LBA strategy to maintain global market competitiveness.

Number of Employees

1,645people

Average Salary

72.1M KRW

Score Calculation Basis

Detailed Financial Score

PER

10.89Industry Average 11.935.0Point

In line with industry avg

PBR

0.85Industry Average 0.894.0Point

In line with industry avg

ROE

7.89Industry Average 4.015.5Point

2.0x industry avg (good)

Debt Ratio

33.99Industry Average 12.430.0Point

2.7x industry avg (risky)

Trend 2023~20255.5 / 10 points

Revenue Growth Rate

2.0 / 3

Avg ▲9.2% (2-year basis)

Operating Profit Growth Rate

0.5 / 3

Avg ▼2.2% (2-year basis)

ROE Trend

3.0 / 4

Avg ROE 8.6% (improving, 3yr)

Detailed News Sentiment

16 totalPositive 13Neutral 2Negative 1Average Sentiment Score 78.4

Neutral
'30년 항암제' 탁소텔 품은 보령…득일까 실일까
보령의 탁소텔 사업권 확보로 해외 진출 확대 계획이 발표되었으나, 기존 시장의 성장 제한과 내재화 속도가 주요 변수로 남아 있다.
Positive
공정위, 보령의 ‘탁소텔’ 영업양수 조건부 승인
보령의 '탁소텔' 영업 양수 승인으로 항암제 시장 내 경쟁력 강화 기대.
Positive
보령 "공정위 '탁소텔 복제약' 매각 조치 성실히 이행할 것"
보령의 탁소텔 인수 조건부 승인 이행 발표로 글로벌 사업 확장 기대.

Detailed Momentum

52-week position1.0Point

Near 52w low (6%, downtrend)

Current 8,340Won52-week high 10,68052-week low 8,170

1-month return1.0Point

1m -13.66% (falling)

Volume trend3.0Point

Volume flat

Detailed Disclosure

4 totalPositive 0Neutral 4Negative 0

Neutral[기재정정]투자판단관련주요경영사항 (유방암 치료제 탁소텔(Taxotere)의 글로벌 비즈니스 인수 계약의 건)2026-06-01
Neutral지속가능경영보고서등관련사항(자율공시)2026-06-01
Neutral기업지배구조보고서공시2026-05-29
Neutral분기보고서 (2026.03)2026-05-14